Gout and risk of non-alcoholic fatty liver disease

Scandinavian Journal of Rheumatology

Volumn 39, Issue 6, 2010, Pages 466-471

  Kuo, C F ^a,b,c   Yu, K H ^c   Luo, S F ^c,d   Chiu, C T ^d,e   Ko, Y S ^c,d   Hwang, J S ^b   Tseng, W Y ^a,c   Chang, H C ^c   Chen, H W ^f   See, L C ^a,f  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b Health Evaluation Centre   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e Division of Gastroenterology and Hepatology   (Taiwan)

^f Biostatistics Consulting Center   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

URATE;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SCREENING; URIC ACID BLOOD LEVEL;

ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GLOMERULAR FILTRATION RATE; GOUT; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; URIC ACID;

EID: 78649710412     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009741003742797     Document Type: Article

References (35)

1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
2. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185-92.
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-19.
5. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109-15.
6. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20:187-91.
7. Lin WY, Liu CS, Li TC, Lin T, Chen W, Chen CC, et al. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). Ann Rheum Dis 2008;67:432-3.
8. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.
9. Shifflet A, Wu GY. Non-alcoholic steatohepatitis: an overview. J Formos Med Assoc 2009;108:4-12.
10. Perez-Ruiz F, Schlesinger N. Management of gout. Scand J Rheumatol 2008;37:81-9.
11. Jansen TL, Reinders MK, van Roon EN, Brouwers JR. Benzbromarone withdrawn from the European market: another case of 'absence of evidence is evidence of absence'? Clin Exp Rheumatol 2004;22:651.
12. Tam S, Carroll W. Allopurinol hepatotoxicity. Am J Med 1989;86:357-8.
13. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6.
14. Bureau of Health Promotion. The criteria of metabolic syndrome. Taiwan: Bureau of Health Promotion, Department of Health, 2003.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. J Am Med Assoc 2003;289:2560-72.
16. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
18. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15.
19. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17(Suppl 3): S377-84.
20. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75-104, ix.
21. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001;34:1158-63.
22. Li XL, Man K, Ng KT, Lee TK, Lo CM, Fan ST. Insulin in UW solution exacerbates hepatic ischemia/reperfusion injury by energy depletion through the IRS-2/SREBP-1c pathway. Liver Transpl 2004;10:1173-82.
23. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
24. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997;92:51-8.
25. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52.
26. Lopez-Suarez A, Elvira-Gonzalez J, Bascunana-Quirell A, Rosal-Obrador J, Michan-Dona A, Escribano-Serrano J, et al. Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome (in Spanish). Med Clin (Barc) 2006;126:321-4.
27. Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, et al. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 2006;24:1633-9.
28. Puig JG, Martinez MA, Mora M, Fraile JM, Montoya F, Torres RJ. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosides Nucleotides Nucleic Acids 2008;27:620-3.
29. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029-34.
30. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21:504-11.
31. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
32. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10.
33. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
34. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
35. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141-6.